Utility of a safety switch to abrogate CD19.CAR T-cell–associated neurotoxicity

2021/02/23 by Matthew C. Foster, Barbara Savoldo, Winnie Lau +21 · 27 citations
Medicine · Engineering · #CAR-T cell therapy research #Integrated Circuits and Semiconductor Failure Analysis

paper · pdf · doi:10.1182/blood.2021010784

Abstract

2] Although many cases of ICANS resolve with supportive measures, high-grade ICANS may result in status epilepticus, lasting neurologic deficits, cerebral edema, 6 and death. 7 Therefore, novel approaches for severe ICANS fill an urgent unmet need to enhance the use of adoptive cellular therapy.

Cited by

• CAR T cells: Building on the CD19 paradigm
• The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials
• CAR T cells: Building on the CD19 paradigm. [europepmc]
• Mechanisms of cytokine release syndrome and neurotoxicity of CAR T-cell therapy and associated prevention and management strategies. [europepmc]
• Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy. [europepmc]
• Cytokine Release Syndrome and Associated Acute Toxicities in Pediatric Patients Undergoing Immune Effector Cell Therapy or Hematopoietic Cell Transplantation. [europepmc]
• Application and Design of Switches Used in CAR. [europepmc]
• Next generations of CAR-T cells - new therapeutic opportunities in hematology? [europepmc]
• Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours. [europepmc]
• Hypoimmune anti-CD19 chimeric antigen receptor T cells provide lasting tumor control in fully immunocompetent allogeneic humanized mice. [europepmc]
• RapaCaspase-9-based suicide gene applied to the safety of IL-1RAP CAR-T cells. [europepmc]
• From bench to bedside: the history and progress of CAR T cell therapy. [europepmc]
• Anti-CD117 CAR T cells incorporating a safety switch eradicate human acute myeloid leukemia and hematopoietic stem cells. [europepmc]
• Regulatory T Cell-Targeted Immunomodulatory Therapy for Long-Term Clinical Improvement of Atopic Dermatitis: Hypotheses and Perspectives. [europepmc]
• Building safety into CAR-T therapy. [europepmc]
• Current Situation and Prospect of Adoptive Cellular Immunotherapy for Malignancies. [europepmc]
• Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting. [europepmc]
• Current understanding and management of CAR T cell-associated toxicities. [europepmc]
• CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations. [europepmc]
• Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies. [europepmc]
• Anti-CD5 CAR-T cells with a tEGFR safety switch exhibit potent toxicity control. [europepmc]
• Infusion and delivery strategies to maximize the efficacy of CAR-T cell immunotherapy for cancers. [europepmc]
• Unlocking T cell exhaustion: Insights and implications for CAR-T cell therapy. [europepmc]
• ReCARving the future: bridging CAR T-cell therapy gaps with synthetic biology, engineering, and economic insights. [europepmc]
• The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials. [europepmc]
• Strategies to Overcome Antigen Heterogeneity in CAR-T Cell Therapy. [europepmc]
• Gene regulation technologies for gene and cell therapy. [europepmc]

Related

• Complete spectrum of adverse events associated with chimeric antigen receptor (CAR)-T cell therapies
• Cytokines mediate increased endothelial-leukocyte interaction and brain capillary plugging during CAR T cell neurotoxicity
• Safe CAR-T: shedding light on CAR-related T-cell malignancies
• Regulatory challenges of personalized medicine in the real world: are the right patients being treated with CD19-targeting CAR T-cells?
• GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts